<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Frontiers in Neurology | New and Recent Articles</title>
        <link>https://www.frontiersin.org/journals/neurology</link>
        <description>RSS Feed for Frontiers in Neurology | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-05-14T05:28:26.18+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1761459</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1761459</link>
        <title><![CDATA[Advancing rehabilitation in Parkinson’s disease through virtual reality: a narrative review]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Pierluigi Diotaiuti</author><author>Francesco Di Siena</author><author>Marco Palombo</author><author>Giulio Marotta</author><author>Elisa Cavicchiolo</author><author>Pio Alfredo Di Tore</author><author>Stefania Mancone</author>
        <description><![CDATA[BackgroundVirtual reality (VR) is increasingly explored in Parkinson’s disease (PD) rehabilitation, yet the clinical evidence remains heterogeneous.ObjectiveTo provide an integrative narrative synthesis of the neurophysiological rationale, VR modalities (immersive, semi-immersive, and non-immersive), and motor/non-motor outcomes associated with VR-based rehabilitation in PD.MethodsNarrative review of peer-reviewed studies published between 2010 and 2025. Fifteen PD + VR rehabilitation studies meeting eligibility criteria were included in the qualitative synthesis. Mechanistic, non-PD, pre-2010, or otherwise non-eligible studies were discussed only as contextual/supporting evidence. Findings were synthesized narratively, and methodological limitations were examined through a structured critical appraisal.ObjectiveAcross small and methodologically heterogeneous samples, VR-based rehabilitation was associated mainly with improvements in balance and gait-related outcomes, including Berg Balance Scale (BBS) scores, Timed Up and Go (TUG) performance, Functional Gait Assessment (FGA), stride length, gait velocity, and walking distance. Selected studies also reported gains in upper-limb function and balance confidence. Effects on freezing of gait and tremor were variable. Cognitive and executive effects were less established than motor findings and should be considered preliminary.ConclusionVR appears promising as an adjunct to conventional rehabilitation in PD, particularly for gait, balance, and motor-cognitive training, but the certainty of evidence remains moderate to low. Broader mechanistic interpretations should be considered plausible explanatory frameworks rather than demonstrated therapeutic effects. Priorities for future research include protocol standardization, blinded assessment, improved safety reporting, sham/yoked comparator designs, responder profiling, and evaluation of scalable home-based and AI-adaptive platforms.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1809677</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1809677</link>
        <title><![CDATA[Comparative effectiveness of moxibustion-based combination therapies for lumbar disc herniation: a systematic review and network meta-analysis of 50 randomized trials]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Dongmin Du</author><author>Shurong Wang</author><author>Shuran Wang</author><author>Han Sun</author><author>Yi Shan</author>
        <description><![CDATA[ObjectiveMoxibustion, a widely utilized external therapeutic technique in traditional Chinese medicine, has become an integral part of non-surgical management for lumbar disc herniation (LDH). This study seeks to perform a systematic review and network meta-analysis (NMA) to evaluate and compare the efficacy of different moxibustion-based combination therapies in the treatment of LDH.MethodsThis study employs NMA to evaluate randomized controlled trials (RCTs) published up to January 14, 2026. A systematic search of the literature was conducted across multiple databases, including PubMed, EMBASE, the Cochrane Library, Web of Science, and Chinese databases such as CNKI and Wanfang Medical Database. The interventions assessed include moxibustion alone, as well as combinations of moxibustion with acupuncture (ACU), tuina (TUINA), lumbar traction (REHAB), traditional Chinese medicine therapy (TCM), and conventional intervention (CT). The primary outcomes include the Visual Analog Scale (VAS) score for pain, the Oswestry Disability Index (ODI) score for functional improvement, and the Japanese Orthopedic Association (JOA) score for clinical symptoms. Statistical analysis was conducted using Stata 17.0 MP, with a random-effects model applied to calculate mean differences (MD) and risk ratios (RR). The quality of evidence was assessed using the GRADE framework.ResultsA total of 50 studies involving 4,399 patients were included in the analysis. The results suggest that, for the JOA score, low to moderate-quality evidence indicates that MOXI+CT (MD = 11.93, 95% CI: 8.88 to 14.98) and MOXI+TUINA (MD = 7.81, 95% CI: 4.4 to 11.23) significantly improved the JOA score compared to CT. For the ODI score, low to moderate-quality evidence indicates that MOXI+ACU (MD = −10.11, 95% CI: −11.92 to −8.3) and MOXI+TUINA (MD = −6.52, 95% CI: −8.58 to −4.46) significantly reduced the ODI score compared to CT. In the case of the VAS score, very low to low-quality evidence suggests that MOXI+ACU (MD = −1.99, 95% CI: −3.06 to −0.92) and MOXI+TUINA (MD = −2.2, 95% CI: −3.4 to −0.99) significantly reduced the VAS score compared to CT. Regarding the cure rate, moderate-quality evidence shows that MOXI+TUINA (RR = 2.45, 95% CI: 1.55 to 3.86) and MOXI+TCM (RR = 1.75, 95% CI: 1.31 to 2.33) significantly improved the cure rate compared to CT.ConclusionModerate to very low evidence indicates that the combination of TUINA+MOXI significantly reduces pain, enhances functional recovery, and promotes overall rehabilitation in patients with LDH. These results suggest that combining moxibustion with other therapeutic approaches may provide an effective non-surgical alternative for the management of LDH.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1740742</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1740742</link>
        <title><![CDATA[A systematic review and meta-analysis of the effects of exercise training on dysfunction in acute, subacute, and chronic stroke patients]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Jing Tan</author><author>Yongyan Tang</author><author>Daobin Han</author>
        <description><![CDATA[ObjectiveThis systematic review and meta-analysis aimed to compare the effectiveness of exercise training initiated in the acute, subacute, and chronic phases after stroke.MethodsThe Wanfang, CNKI, VIP, PubMed, Web of Science, Cochrane Library, and EMBASE databases were comprehensively searched for relevant articles from their inception to December 2025. Studies comparing outcomes among the acute stage exercise training group (ASETG), subacute stage exercise training group (SSETG), and chronic stage exercise training group (CSETG) for stroke patients were included. The outcomes assessed were improvements in the Fugl-Meyer Assessment (FMA), Berg Balance Scale (BBS), Action Research Arm Test (ARAT), Modified Barthel Index (MBI), and Modified Ashworth Scale (MAS) after treatment. Meta-analysis of comparable data was performed using Review Manager 5.3 software provided by the Cochrane Collaboration.ResultsA total of 16 randomized controlled trials (RCTs) and 22 observational studies involving 5,254 patients were included. The meta-analysis indicated that the ASETG showed significantly greater improvements in FMA scores compared to the SSETG [WMD = 7.95, 95% CI (6.73, 9.16)]. This trend was also observed in the FMA-UE [WMD = 4.26, 95% CI (3.09, 5.44)] and FMA-LE [WMD = 4.57, 95% CI (3.73, 5.41)] subscales when compared to the SSETG. Furthermore, the ASETG outperformed the CSETG in FMA scores [WMD = 5.31, 95% CI (3.89, 6.72)]. In addition, the ASETG exhibited significantly greater improvements in BBS scores compared to the SSETG [WMD = 3.64, 95% CI (1.14, 6.15)] and in MBI scores [WMD = 10.66, 95% CI (9.55, 11.77)]. Moreover, the SSETG showed a greater improvement in ARAT scores compared to the CSETG [WMD = 2.70, 95% CI (1.81, 3.59)].ConclusionThis review suggests earlier post-stroke exercise may improve functional outcomes (FMA, BBS, MBI, ARAT). However, due to heterogeneity and inclusion of observational studies, findings should be interpreted cautiously. High-quality RCTs are needed to confirm the optimal timing.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024519257, identifier PROSPERO (CRD42024519257).]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1777478</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1777478</link>
        <title><![CDATA[Middle-aged predominance and diagnostic delays in anti-LGI1 encephalitis: the role of antibody testing]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Shu Kan</author><author>Gege Zhang</author><author>Hua Yu</author><author>Hongmei Ding</author>
        <description><![CDATA[BackgroundThis study aimed to investigate the clinical characteristics of anti-leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis and to identify significant risk factors associated with long-term functional prognosis.MethodsWe retrospectively analyzed the clinical data of 20 patients diagnosed with anti-LGI1 encephalitis at the Affiliated Hospital of Xuzhou Medical University from January 2021 to October 2024. All patients underwent a 12-month follow-up. Functional outcomes were assessed using the modified Rankin Scale (mRS) at 12 months post-discharge and were dichotomized into favorable (mRS ≤ 2) and poor (mRS > 2) outcome groups.ResultsOf the 20 patients (14 males and 6 females; mean age: 57 years), seizures represented the most prevalent chief complaint at onset (70%). Cognitive impairment was noted as an initial presenting symptom in 45% of patients, whereas its cumulative incidence reached 95% throughout the entire disease course. Pathognomonic faciobrachial dystonic seizures (FBDS) occurred in 40% of cases, and hyponatremia was present in 70% of the cohort. Anti-LGI1 antibodies were detected in 95% (19/20) of serum samples and 90% (18/20) of cerebrospinal fluid (CSF) samples. Notably, 40% of patients exhibited unremarkable cranial MRI findings, and 55% demonstrated normal CSF protein levels upon admission. At the 12-month follow-up, 80% of patients achieved favorable functional recovery. Univariate analysis revealed that advanced age (p = 0.006), prolonged diagnostic delay (p = 0.009), and higher antibody titers in both serum (p = 0.005) and CSF (p = 0.009) were significantly correlated with poor functional outcomes.ConclusionThe high frequency of unremarkable results in initial ancillary investigations, such as MRI and routine CSF analysis, often leads to substantial diagnostic and therapeutic delays in anti-LGI1 encephalitis. Advanced age, diagnostic latency, and high antibody titers are critical predictors of poor prognosis. Early and simultaneous antibody screening in both serum and CSF is essential for narrowing the diagnostic window and optimizing long-term neurological recovery.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1695091</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1695091</link>
        <title><![CDATA[Determination of patient prognosis based on unruptured basilar artery aneurysm morphology using a novel dynamic prediction model]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Wei Wang</author><author>Shilin Liu</author><author>Yifan Fu</author><author>Xiaoxuan Li</author><author>Minghao Xu</author><author>Xiaochan Xu</author><author>Tao Jiang</author>
        <description><![CDATA[IntroductionThe study aimed to develop a novel predictive system to assess the clinical survival of patients with basilar artery aneurysms (BAAs) following endovascular embolization by analyzing aneurysm and peripheral vessel morphologies.MethodsFifty-eight BAA patients who underwent endovascular embolization were retrospectively studied, with a median follow-up of 17.5 months. A total of nine deaths (15.5%) occurred during the follow-up period. Due to the limited number of outcome events, we adopted a conservative modeling strategy that involved using the least absolute shrinkage and selection operator (LASSO)-penalized Cox regression for variable selection, followed by multivariable Cox regression to construct the prognostic model. An online dynamic nomogram was developed to predict survival. Model discrimination was evaluated using the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves. Internal validation was performed using bootstrap resampling with calibration curves, and clinical utility was assessed using decision curve analysis (DCA).ResultsLASSO-penalized Cox regression identified two independent prognostic factors—basilar artery (BA) diameter and aneurysm neck—which were subsequently confirmed by multivariable Cox regression (BA: HR = 2.12, 95% CI: 1.01–4.45, p = 0.047; aneurysm neck: HR = 2.29, 95% CI: 1.04–6.23, p = 0.003). The model demonstrated acceptable discrimination, with a C-index of 0.805. Calibration curves showed good agreement between predicted and observed survival rates. The DCA demonstrated superior net benefit across a broad range of threshold probabilities (0–100%), with a net reduction of more than 80 unsuccessful procedures per 100 patients at a threshold of 85%.ConclusionThis morphology-based, online, dynamic nomogram serves as a practical tool for predicting survival in BAA patients after endovascular embolization. However, given the limited sample size and the number of events, the findings should be considered exploratory, and external validation in larger cohorts is warranted.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1764551</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1764551</link>
        <title><![CDATA[Renal dysfunction and metabolic alterations in patients with intracranial aneurysm rupture: an exploratory multivariable and principal component analysis]]></title>
        <pubdate>2026-05-14T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Zisheng Liu</author><author>Xidong Wu</author><author>Jiaming Xu</author><author>Jianyong Cai</author><author>Huajun Ba</author><author>Qun Lin</author><author>Jun Sun</author><author>Weizhong Shi</author>
        <description><![CDATA[Background and purposeIntracranial aneurysm rupture causes aneurysmal subarachnoid hemorrhage (aSAH) with substantial morbidity and mortality. We examined whether admission renal and metabolic indices differed according to rupture status at presentation in a treated intracranial aneurysm cohort. We examined associations between admission renal/metabolic indices and rupture status in a treated aneurysm cohort.Materials and methodsWe retrospectively reviewed 824 consecutive patients with intracranial aneurysms treated at a single center (January 2018–January 2024), including 344 ruptured aneurysms and 480 treated high-risk unruptured aneurysms. Clinical and laboratory variables were derived from the first admission sample set obtained prior to aneurysm-directed intervention. Univariable and multivariable logistic regression were used to evaluate associations with rupture status at presentation. Principal component analysis (PCA) summarized correlated domains among variables differing between groups. Apparent discrimination in the derivation cohort was assessed using the area under the ROC curve (AUC).ResultsCompared with the unruptured group, ruptured patients were younger and had higher admission blood pressure and higher serum creatinine and blood urea nitrogen (BUN), along with more frequent ketonuria and higher urine specific gravity. In multivariable analysis, age (aOR 0.97 per year), systolic blood pressure (aOR 1.02 per mmHg), serum creatinine (aOR 4.91), BUN (aOR 1.06), LDH (aOR 1.01), ketonuria (aOR 3.74), and urine specific gravity (aOR 1.50) remained independently associated with rupture status at presentation, while a history of hypertension (aOR 0.66) and higher potassium, chloride, and calcium were inversely associated. PCA identified three components explaining 50.3% of variance, dominated by renal/hemodynamic indices, urinary abnormalities, and electrolyte indices, respectively. The derivation model demonstrated apparent discrimination within the analyzed cohort (AUC 0.85), without internal or external validation.ConclusionRenal- and metabolic-related indices measured at admission were associated with rupture status at presentation in this retrospective cohort. Given post-ictus sampling, potential reverse causality, incomplete aneurysm imaging covariates in the full cohort, and limited ascertainment of baseline renal comorbidities (CKD/ADPKD), these findings should be interpreted as hypothesis-generating correlates rather than pre-rupture predictors and warrant prospective validation with standardized sampling timepoints and comprehensive imaging adjustment.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1829149</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1829149</link>
        <title><![CDATA[Machine learning-based prediction of ischemic cardio-cerebrovascular events after endovascular or microsurgical treatment of unruptured intracranial aneurysms and risk stratification by the early post-treatment triglyceride-glucose index]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Yingchao He</author><author>Shuheng Chen</author><author>Deshan Liu</author><author>Zheng Zheng</author><author>Yongkun Li</author><author>Yinzhou Wang</author>
        <description><![CDATA[BackgroundIschemic cardio-cerebrovascular events (ICCEs), including acute coronary syndrome and ischemic cerebral infarction, remain clinically important complications after endovascular or microsurgical treatment of unruptured intracranial aneurysms (UIAs). However, early identification of patients at high post-treatment ischemic risk remains challenging, and reliable risk-stratification tools are lacking.ObjectiveTo develop a machine learning-based framework for predicting ischemic cardio-cerebrovascular events (ICCEs) within 6 months after treatment in patients with unruptured intracranial aneurysms (UIAs) and to evaluate the risk-stratification value of the early post-treatment triglyceride-glucose (TyG) index.MethodsA total of 1,954 patients with UIAs who underwent microsurgical or endovascular treatment between December 2021 and December 2024 were enrolled from the China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA) registry. Nine predictive models, including logistic regression as a baseline comparator, were evaluated after feature selection using least absolute shrinkage and selection operator regression and the Boruta algorithm. The synthetic minority over-sampling technique was used to address class imbalance. Model performance was assessed by discrimination, calibration, and clinical utility metrics, and the optimal model was interpreted using SHapley Additive exPlanations. The association between the post-treatment day-3 TyG index and ICCEs was analyzed using multivariable Cox regression, restricted cubic spline analysis, and subgroup analyses.ResultsDuring the 6-month follow-up, 240 of 1,954 patients (12.28%) developed ICCEs. Of the included patients, 1,343 underwent endovascular treatment and 611 underwent microsurgical treatment. Among all models, CatBoost achieved the best overall performance, with an accuracy of 0.875 and an area under the receiver operating characteristic curve (AUROC) of 0.945 (95% CI, 0.927–0.963). SHAP analysis identified the post-treatment TyG index as one of the most influential predictors. In multivariable analysis, each 1-unit increase in TyG was associated with a 2.61-fold higher hazard of ICCEs (HR = 2.61, 95% CI: 2.29–2.96, p < 0.001). Restricted cubic spline analysis showed a nonlinear positive association with a clear threshold effect at approximately TyG = 7.ConclusionThe CatBoost model demonstrates strong predictive performance for post-treatment ICCEs in UIA patients. The early post-treatment TyG index is independently and nonlinearly associated with ICCE risk and may serve as a simple, practical metabolic marker for individualized perioperative risk stratification.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1821856</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1821856</link>
        <title><![CDATA[Acute glycemic variability and short-term mortality of patients with subarachnoid hemorrhage: a meta-analysis]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Lin Huang</author><author>Le Xie</author><author>Dahua Wu</author>
        <description><![CDATA[BackgroundAcute glycemic variability (GV) has been proposed as a potential prognostic marker in critically ill patients, but its association with mortality in subarachnoid hemorrhage (SAH) remains unclear. We conducted a meta-analysis to evaluate the relationship between acute GV and short-term mortality in patients with SAH.MethodsPubMed, Embase, Web of Science, Wanfang, and CNKI were searched from inception to identify longitudinal observational studies assessing acute GV during hospitalization and reporting short-term mortality (≤90 days) in adult patients with SAH. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using random-effects models accounting for the influence of potential heterogeneity.ResultsSeven cohort studies involving 10,119 patients were included, among whom 2,485 (24.6%) died within 90 days. Pooled results suggested that high acute GV was significantly associated with increased short-term mortality (OR 1.64, 95% CI 1.34–2.01; p < 0.001; I2 = 15%). Subgroup analyses showed a stronger association was observed in studies with glucose monitoring > 3 days compared with ≤3 days (OR 2.62 vs. 1.48; p for subgroup difference = 0.03). Further subgroup analyses suggested that the association was consistent across subgroups stratified by study design, geographic region, mean age, sex distribution, diabetes proportion, follow-up duration, and study quality (all p for subgroup differences > 0.05).ConclusionHigher acute GV was associated with increased short-term mortality in patients with SAH. Prolonged glucose monitoring may enhance prognostic value. These findings suggest that acute glucose fluctuations may serve as a risk factor for short-term mortality in patients with SAH.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/search, identifier CRD420261330574.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1792705</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1792705</link>
        <title><![CDATA[Association of steroid regimens and withdrawal with relapse risk in myasthenia gravis: a real-world cohort study]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Yangyu Huang</author><author>Ying Tan</author><author>Jingwen Yan</author><author>Yuzhou Guan</author>
        <description><![CDATA[BackgroundCorticosteroids (steroids) are the first-line immunotherapy for myasthenia gravis (MG), but the optimal steroid dosing regimen and effects of discontinuation remain unclear. This study aimed to investigate the associations of steroid regimens and steroid withdrawal with relapse risk in patients on steroid monotherapy.MethodsThis cohort study, based on a prospective registry, included MG patients who achieved minimal manifestations or better status for at least 6 months with steroid monotherapy. The primary outcome was relapse. Group-based trajectory modeling (GBTM) identified steroid regimens, and Cox proportional hazards models with propensity score matching (PSM) assessed the association of regimens and steroid withdrawal with relapse.ResultsAmong 209 patients followed for a median of 54.0 months, 113 (54.1%) experienced relapses. GBTM identified three regimens reflecting baseline disease severity: “High Start, Fast Taper” (Regimen 1), “Moderate Start, Gradual Taper” (Regimen 2), and “Low Start, Slow Taper” (Regimen 3). Compared to the high-risk Regimen 1, Regimen 2 (HR = 0.27, p < 0.001) and Regimen 3 (HR = 0.15, p < 0.001) were associated with significantly lower relapse risks. A statistically determined cut-off analysis found that requiring a maximum induction dose >0.83 mg/kg to achieve MM or better status was a predictor of relapse (HR = 1.54, p = 0.033). Sixty-eight (32.5%) withdrew steroids, and PSM showed that steroid withdrawal significantly increased relapse risk versus low-dose maintenance (HR = 1.64, p = 0.009).ConclusionIn this steroid-responsive population, patients requiring a maximum induction dose > 0.83 mg/kg to achieve MM or better status have a significantly higher risk of future relapse. Steroid withdrawal is associated with a higher relapse risk compared to low-dose maintenance and should be approached with caution.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1776618</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1776618</link>
        <title><![CDATA[Proportions, trends, and outcomes of posterior circulation ischemic stroke in the United States]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Adnan I. Qureshi</author><author>Nived Jayaraj Ranjini</author><author>David Cohen</author><author>Shahhan Spall</author><author>Akash Roy</author><author>Christy N. Cassarly</author><author>Renee H. Martin</author><author>William J. Powers</author><author>Chun Shing Kwok</author>
        <description><![CDATA[BackgroundPosterior circulation ischemic stroke has been previously studied in single-center and multicenter registries. The contemporary proportions, trends, and outcomes of posterior circulation ischemic stroke at a national level are not known.MethodsWe identified patients admitted with ischemic stroke using the Nationwide Inpatient Sample from 2016 to 2022. We compared the rates of intravenous (IV) thrombolysis, thrombectomy, in-hospital mortality, routine discharge without palliative care (based on discharge disposition), and length and costs of hospitalization in patients admitted with posterior circulation ischemic stroke to patients admitted with anterior circulation ischemic stroke.ResultsAmong 4,773,715 ischemic stroke admissions, 1,675,030 (35.1%) had a territory-specific localization code and 1,630,520 were included for analysis. A total of 383,990 (23.6%) and 1,246,530 (76.4%) patients were admitted with posterior and anterior circulation ischemic stroke, respectively. From 2016 to 2022, the number of patients admitted with posterior circulation ischemic strokes increased from 42,055 in 2016 to 73,755 in 2022, demonstrating a temporal trend (p trend p < 0.001). Patients with posterior circulation ischemic stroke were more likely to have diabetes mellitus and less likely to have heart failure and atrial fibrillation. The proportion of patients with a National Institutes of Health Stroke Scale (NIHSS) score of 0–4 was significantly higher in patients with posterior circulation ischemic stroke (63.8% vs. 40.8%). The utilization of IV thrombolysis (6.1% vs. 13.3%) and thrombectomy (4.0% vs. 16.4%) was lower in patients with posterior circulation ischemic stroke compared with those with anterior circulation ischemic stroke. The in-hospital mortality was significantly higher [odds ratio 1.53, 95% CI: (1.45–1.63), p < 0.001] in patients with posterior circulation ischemic stroke after adjusting for potential confounders, including NIHSS score strata.ConclusionsOver 20% of acute ischemic strokes occur in posterior circulation territories in the United States. Patients with posterior circulation ischemic stroke are less likely to receive acute stroke treatment compared with those with anterior circulation ischemic stroke.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1788639</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1788639</link>
        <title><![CDATA[Rehmannioside A alleviates neuroinflammation and cognitive impairments after traumatic brain injury by suppressing microglial activation via the MAPK/NF-κB pathway]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Shiyu Zhou</author><author>Yiwan Fang</author><author>Haoxin Ji</author><author>Huazheng Yan</author><author>Jianxiong Gao</author><author>Hezuo Lü</author>
        <description><![CDATA[BackgroundTraumatic brain injury (TBI) triggers a robust neuroinflammatory response characterized by microglial activation, which propagates secondary neuronal damage and contributes to long-term neurological deficits. Rehmannioside A (REA), a principal bioactive compound from Rehmannia glutinosa, has emerged as a candidate for neuroprotection due to its anti-inflammatory properties. However, its therapeutic potential and precise mechanisms of action in TBI remain to be fully elucidated.MethodsWe employed a controlled cortical impact (CCI) model in mice to mimic clinical TBI. Animals were randomized into Sham/Veh, Sham/REA, TBI/Veh, and TBI/REA (40 mg/kg) groups. Neurological and cognitive functions were assessed using the modified Neurological Severity Score (mNSS) and Morris Water Maze (MWM). Cerebral edema was measured, and histopathological changes were evaluated by H&E and Nissl staining. LPS-stimulated BV2 microglial cells were used for in vitro experiments. Pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assay (ELISA) and qRT-PCR, and activation of the MAPK/NF-κB pathway was analyzed by western blotting.ResultsREA treatment significantly improved neurological scores, spatial learning and memory, and reduced cerebral edema and neuronal loss in TBI mice. REA suppressed microglial activation in vivo and dose-dependently inhibited LPS-induced pro-inflammatory mediators in vitro. These beneficial effects are associated with reduced phosphorylation of p65 (NF-κB) and p38 (MAPK) in activated microglia in vitro.ConclusionREA ameliorates functional deficits and neuropathology following TBI. The neuroprotective effect may involve suppression of microglia-mediated neuroinflammation via inhibition of the MAPK/NF-κB signaling pathway.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1754777</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1754777</link>
        <title><![CDATA[Efficacy of non-pharmacological treatments for prolonged disorders of consciousness: a network meta-analysis of randomized controlled trials]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Chunyue Xu</author><author>Han Yang</author><author>Wenyue Cai</author><author>Qun Liu</author><author>Mingjia Zhang</author><author>Hongge Zuo</author><author>Jianbang Su</author><author>Jingqi Shu</author><author>Zhenhua Xu</author>
        <description><![CDATA[ObjectiveTo explore the efficacy of non-pharmacological treatments such as repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), median nerve stimulation (MNS), hyperbaric oxygen (HBO), and acupuncture in improving the level of consciousness in patients with prolonged disorders of consciousness (pDOC).MethodsPubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, China Biology Medicine (CBM), and VIP Database were systematically searched from inception to December 2024. Data synthesis and visualization were conducted using the “coda” and “gemtc” packages in R software and STATA 17.0. The Jadad scale was used for initial screening to exclude low-quality studies, and the Cochrane Risk of Bias 2.0 tool was applied to assess the methodological quality of included randomized controlled trials (RCTs).ResultsA total of 32 randomized controlled trials (RCTs) enrolling 1,770 participants were included in this network meta-analysis. The pooled results demonstrated that rTMS, tDCS, MNS, HBO, and acupuncture were all associated with improved scores on the Coma Recovery Scale-Revised (CRS-R). The mean difference (MD) ranged from 17.32 (95% CrI: 6.57 to 104.25) in the rTMS group to 3.56 (95% CrI: 0.61 to 40.45) in the acupuncture group. According to the Surface Under the Cumulative Ranking Curve (SUCRA), rTMS was associated with the highest probability of being the most effective intervention. In subgroup analyses, among patients with minimally conscious state (MCS), the MD ranged from 15.99 (95% CrI: 1.57 to 66.77) in the tDCS group to 9.72 (95% CrI: 2.07 to 61.04) in the MNS group, and among patients with unresponsive wakefulness syndrome (UWS), the MD ranged from 18.52 (95% CrI: 2.15 to 108.73) in the rTMS group to 4.12 (95% CrI: 0.25 to 69.30) in the acupuncture group.ConclusionrTMS, tDCS, MNS, HBO, and acupuncture may improve CRS-R scores and promote consciousness recovery in patients with pDOC. Among these interventions, tDCS may be associated with more favorable effects in patients with MCS, whereas rTMS appears to be more beneficial for those with UWS.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1802799</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1802799</link>
        <title><![CDATA[Study on the effects and mechanisms of rhythmic auditory stimulation on freezing of gait in Parkinson’s disease: investigation based on functional near-infrared spectroscopy (fNIRS) technology]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Lingyu Sheng</author><author>Ziyao Zhang</author><author>Guiyun Cui</author><author>Jie Xiang</author>
        <description><![CDATA[IntroductionFreezing of gait (FOG) in Parkinson’s disease (PD) patients is a critical determinant of motor impairment and fall risk. Rhythmic auditory stimulation (RAS) has been shown to ameliorate FOG symptoms, although the underlying neurophysiological mechanisms are not fully understood.ObjectivesThis research employed functional near-infrared spectroscopy (fNIRS) to analyze three RAS—two external auditory cueing strategies (beat perception and music therapy) and one internal cueing method (mental beat imagery)—to examine gait parameters and cortical activation patterns in Parkinson’s disease patients with freezing of gait (PD + FOG) compared to healthy controls (HC). The study also sought to evaluate the therapeutic effectiveness of these rhythm-based interventions in alleviating FOG episodes.MethodsTwenty-eight patients with PD + FOG and twenty-eight age-matched HC were enrolled in the study. Gait analysis was performed during narrow corridor ambulation, designed to induce freezing episodes, and during straight-line walking in an open environment. fNIRS was employed to measure fluctuations in oxygenated hemoglobin (HbO2) and deoxygenated hemoglobin (HHb) concentrations, serving as indicators of cortical activation. Regions of interest (ROIs) included the prefrontal cortex (PFC), premotor cortex (PMC), and temporal cortex (TLC). Intracortical functional connectivity during each locomotor task was evaluated through correlation analyses of HbO2 signals between the ROIs.ResultsPD + FOG patients exhibited gait disturbances characterized by reduced gait velocity and stride length, along with increased mediolateral postural sway during freezing episodes. Neuroimaging indicated significantly decreased activation in the primary somatosensory cortex (S1), PMC, and PFC compared to healthy controls, despite elevated intracortical connectivity involving indirect corticospinal pathways. Differential responses to RAS interventions were noted: rhythmic auditory cues enhanced connectivity between TLC and PMC; music therapy significantly improved PFC intrinsic connectivity; whereas imagined auditory cues potentially impaired sensorimotor integration due to excessive reliance on internal cognitive mechanisms.ConclusionVarious RAS pathways can ameliorate freezing of gait symptoms by selectively modulating functional connectivity between the prefrontal cortex and sensorimotor circuits. The underlying neural mechanisms may largely involve neural entrainment and reorganization of brain networks. These results offer vital empirical insights into the pathophysiology of gait freezing and provide a preliminary theoretical basis for designing precision neuromodulation interventions.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1776595</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1776595</link>
        <title><![CDATA[Long-term outcomes of endovascular thrombectomy vs. medical care in patients with large ischemic stroke: a systematic review and meta-analysis of randomized controlled trials]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Jiayu You</author><author>Hang Zhou</author><author>Qianshuo Liu</author><author>Xingqiang Li</author>
        <description><![CDATA[BackgroundSeveral randomized controlled trials (RCTs) have shown endovascular thrombectomy (EVT) to be superior to standard medical care (MC) for anterior circulation large vessel occlusion (LVO)-related large ischemic infarcts at the 90-day follow-up, but long-term (≥90 days) safety and effectiveness evidence is lacking.ObjectivesThis meta-analysis used high-quality RCTs (1-year follow-up) to assess EVT’s clinical benefits in this patient group and compare short- vs. long-term prognostic changes.Search methodsLiterature searches were conducted in PubMed/MEDLINE, Scopus, and Web of Science from their inception to 28 September 2025 for RCTs comparing EVT and MC in acute anterior circulation ischemic stroke (AIS) with large ischemic infarcts. Study quality was evaluated using the Cochrane risk of bias tool.Selection criteriaThese included RCTs enrolled patients with confirmed anterior circulation LVO and low Alberta Stroke Program Early CT Score [ASPECTS] ≤ 5, compared EVT and MC, and reported long-term outcome data.Data collection and analysisA meta-analysis of long-term functional/safety outcomes was performed; subgroup analyses were performed based on onset time, ASPECTS, and imaging screening methods, along with leave-one-out sensitivity analysis.ResultsBaseline characteristics were balanced between the groups, and all included RCTs were high-quality. At long-term follow-up (>90 days to 12 months), EVT significantly improved functional excellence [modified Rankin Scale 0–1; risk ratio (RR) = 3.84, 95% confidence interval (CI) = 2.35–6.28; p < 0.001], functional independence (modified Rankin Scale 0–2; RR = 3.13, 95%CI = 2.01–4.86; p < 0.001), and independent ambulation (modified Rankin Scale 0–3; RR = 2.01, 95%CI = 1.52–2.67; p < 0.001) in patients with anterior circulation large ischemic infarcts; mortality was not significantly different between groups (RR = 0.90, 95%CI = 0.78–1.05; p = 0.19). EVT also reduced the risk of death or dependency (modified Rankin Scale 4–6; RR = 0.78, 95%CI = 0.73–0.84; p < 0.001). Long-term follow-up revealed more significant prognostic improvements with EVT compared with short-term follow-up.ConclusionIn AIS patients with anterior circulation LVO-related large ischemic infarcts, EVT plus MC yielded statistically significant long-term functional improvements compared with MC alone. EVT’s benefits were amplified with longer follow-up and were more pronounced in patients with shorter onset time and smaller infarct volume.Systmatic review registraionhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251144703, CRD420251144703.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1789311</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1789311</link>
        <title><![CDATA[Pre-hospital delay and its influencing factors in patients with acute ischemic stroke: a cross-sectional study based on the health ecology model]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Juan Wei</author><author>Qiaowei Li</author><author>Xing Liu</author><author>Lingling Ji</author><author>Cuiyun Zhang</author>
        <description><![CDATA[Background and objectiveThe treatment of acute ischemic stroke (AIS) is time-dependent, and pre-hospital delays remain a significant barrier to effective stroke management worldwide. Previous studies have often focused on isolated factors; however, the problem is multifaceted. This study lies in applying the Health Ecology Model as a comprehensive framework to systematically investigate the multifaceted factors (Intrapersonal, Interpersonal, Community, and Policy environment levels) associated with pre-hospital delay among AIS patients.MethodsA cross-sectional study was conducted, we consecutively enrolled 439 AIS patients admitted to the stroke center of a tertiary hospital in Guangzhou between January and December 2024. Data were collected through structured questionnaires and medical records, specifically aligned with the constructs of the Health Ecology Model. Measures included Intrapersonal level: Individual characteristics (e.g., number of stroke occurrences, symptoms at onset, mode of onset) and Behavioral and psychological factors (e.g., number of physical examination, Health literacy). Interpersonal level: family function (Family APGAR Index) and social support (Social Support Rating Scale). Community level: Living and working conditions (e.g., Employment status, Present residence). Policy environment level (e.g., Payment method, Awareness to call 120 for stroke emergency). Pre-hospital delay was defined as an onset-to-door time>6 h. Multivariable logistic regression identified independent influencing factors.ResultsThe pre-hospital delay rate was 54.44%. Significantly, factors from multiple levels of the Health Ecology Model were independently associated with delay: Lower stroke awareness(OR = 5.414, 95% CI 2.291–12.794), Perception of symptom severity (OR = 31.798, 95% CI 13.119–77.077), limb weakness /numbness (OR = 3.661, 95% CI 1.221–10.979), lower health literacy (OR = 1.064, 95% CI 1.041–1.088), poorer family function (OR = 1.545, 95% CI 1.138–2.097), lower social support (OR = 1.466, 95% CI 1.322–1.627), and stroke onset during the night (OR = 0.160, 95% CI 0.064–0.401),which increased the odds of delay.ConclusionPre-hospital delay is highly prevalent and is influenced by a complex interplay of factors across individual, family, and systemic levels, as elucidated by the Health Ecology Model. Our findings highlight the critical need to move beyond patient education alone and implement integrated, multi-level interventions. Public health campaigns should target both patients and their families to improve symptom recognition and health literacy. Concurrently, healthcare systems must be optimized, for instance by addressing barriers to after-hours care and strengthening pre-hospital pathways to ensure rapid triage to comprehensive stroke centers, ultimately improving access to timely revascularization therapies.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1834087</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1834087</link>
        <title><![CDATA[Translation, cross-cultural adaptation, validation, and diagnostic properties of the Arabic version of self-diagnosis questionnaire for Benign Paroxysmal Positional Vertigo]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Ahmad A. Alharbi</author><author>Mohammad B. Alkhodair</author><author>Abdulaziz A. Albalwi</author><author>Hamad S. Al Amer</author><author>Akram M. Abdelrahman</author><author>Faisal M. Alzuhair</author><author>Nawaf N. Alsulami</author><author>Abrar H. Alhazmi</author>
        <description><![CDATA[Benign Paroxysmal Positional Vertigo (BPPV) is a common peripheral vestibular disorder, yet no validated Arabic BPPV-specific questionnaire is currently available. To translate and culturally adapt the self-diagnosis BPPV questionnaire into Arabic and to evaluate its psychometric and diagnostic properties. Following cross-cultural adaptation in accordance with established guidelines, 88 participants completed the Arabic version of the questionnaire. Psychometric and diagnostic properties were evaluated. Content validity was excellent (item-level indices ranging from 0.94 to 1.00 for both clarity and relevance, and a scale-level index of 0.98). Convergent validity demonstrated moderate to substantial agreement with positional test results (Cohen's κ values reaching 0.69). Known-groups validity showed fair to excellent discriminative ability (area under the curve values up to 0.84). Internal consistency was moderate for the screening questions (Cronbach's α = 0.720) but lower for subtype determination questions (Cronbach's α = 0.532). The screening component correctly classified (81.8%) participants, with sensitivity, specificity, PPV, NPV, PLR, and NLR of 87.2%, 75.6%, 80.4%, 83.8%, 3.58, and 0.17, respectively. Agreement for the affected ear and BPPV subtype was limited, with many undetermined cases. The Arabic self-diagnosis BPPV questionnaire demonstrated strong content validity, acceptable construct validity, and good diagnostic performance for screening BPPV.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1820825</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1820825</link>
        <title><![CDATA[Disease-specific divergence of inflammatory and metabolic biomarkers in neurocritical neuromuscular disorders]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Sezgin Kehaya</author><author>Erdi Şensöz</author>
        <description><![CDATA[BackgroundMyasthenia gravis (MG) and Guillain–Barré syndrome (GBS) are immune mediated neuromuscular disorders that may require intensive immunotherapy and respiratory support. Although inflammatory biomarkers have been explored in both conditions, their diagnosis specific prognostic value remains unclear. We aimed to compare hemogram-derived inflammatory indices and metabolic injury-related biomarkers in hospitalized MG and GBS patients and to evaluate their associations with disease severity and clinical outcomes.MethodsThis retrospective cohort study included 162 patients (88 MG, 74 GBS) treated with intravenous immunoglobulin and/or plasma exchange. Hemogram-derived indices (neutrophil-to-lymphocyte ratio [NLR], systemic immune–inflammation index [SII]), classical inflammatory markers, and metabolic biomarkers including lactate dehydrogenase (LDH) and the LDH to albumin ratio (LAR) were analyzed in relation to neurological severity, length of hospital stay (LOS), and mechanical ventilation (MV). Receiver operating characteristic analyses and diagnosis-specific multivariable logistic regression models were performed.ResultsMechanical ventilation occurred in 10.5% of patients and was strongly associated with baseline neurological severity in both disorders (p < 0.001). In MG, hemogram-derived indices (particularly NLR and SII) demonstrated good discriminatory performance for severe disease and were associated with adverse outcomes. LDH-based parameters, particularly LAR, which may reflect metabolic stress, were associated with disease severity and respiratory involvement in MG. In GBS, outcomes were predominantly determined by neurological severity measures, whereas inflammatory indices showed limited and inconsistent prognostic value. Post-treatment transaminase elevations were modestly associated with more severe disease in GBS. In multivariable models, baseline clinical severity remained the most consistent determinant of mechanical ventilation across both conditions.ConclusionsBiomarker utility differs between MG and GBS. In MG, inflammatory indices and LDH-based parameters, particularly the LAR, were associated with disease severity and may support risk stratification, including identification of patients at risk for respiratory deterioration. These findings are exploratory and require prospective validation. In GBS, outcomes remain primarily determined by neurological severity.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1808282</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1808282</link>
        <title><![CDATA[Integrating multi-omics and machine learning to explore the role of amino acid metabolism in intervertebral disk degeneration]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Xusheng Li</author><author>Ahmad Nazrun Shuid</author><author>Mohd Fairudz Mohd Miswan</author><author>Xiao Zhang</author><author>Wenbo Gu</author><author>Donghui Cao</author><author>Jungang Wang</author><author>Ziyang Jiang</author><author>Haifeng Yuan</author>
        <description><![CDATA[ObjectiveIntervertebral disk degeneration (IDD) is the leading cause of chronic low back pain, yet its link to amino acid metabolic reprogramming remains unclear.MethodsThree GEO transcriptomes were integrated; amino-acid-metabolism genes were intersected with differentially expressed genes. Core genes were selected by LASSO, SVM and random forest, incorporated into an SHAP-interpretable nomogram, and tested by single-cell analysis, in silico knockout, docking and WB.ResultsForty-three altered amino acid metabolism-related genes were identified, from which five core genes were screened: CETP, AIFM1, and GM2A were up-regulated; PNPLA2 and AGK were down-regulated. The constructed nomogram prediction model achieved an AUC value of 0.812. Degenerated intervertebral disks exhibited increased immune infiltration; the core genes either suppressed protective matrix genes or impaired stress defense capability. Molecular docking results showed that NVP-AEW541 and EGCG could bind to the AIFM1 protein with a binding free energy of −10.7 kcal/mol; WB confirmed protein trends.ConclusionThe five-core-gene signature is strongly associated with IDD and may represent a key regulatory pathway, offering a promising diagnostic model and potential therapeutic targets.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1827022</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1827022</link>
        <title><![CDATA[Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Hideyo Kasai</author><author>Taro Yasumoto</author><author>Shota Kosuge</author><author>Ayako Osanai</author><author>Keita Mizuma</author><author>Akinori Futamura</author><author>Takeshi Kuroda</author><author>Kenjiro Ono</author><author>Hidetomo Murakami</author>
        <description><![CDATA[IntroductionLong-term real-world evidence beyond 24 months for anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies is scarce, particularly regarding treatment persistence and planned discontinuation after goal attainment.MethodsWe conducted a single-center retrospective study of consecutive patients aged ≥15 years who initiated galcanezumab or fremanezumab (monthly/quarterly) between May 2021 and June 2022. Specifically, patients aged ≥15 years with episodic migraine (EM; <15 headache days/month), high-frequency EM (HFEM; 8–14 days/month), or chronic migraine (CM; ≥15 days/month) were included according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. The outcomes included monthly migraine days (MMDs), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test (HIT-6), and the Visual Analogue Scale (VAS), which were assessed at baseline and at 1, 3, 6, 12, and 36 months. Responder rates (RRs) (≥50%, ≥75, and 100%) and continuation/discontinuation reasons were summarized with prespecified and sensitivity analyses. The primary subgroup analysis was prespecified as EM vs. HFEM+CM.ResultsOverall, 50 patients were analyzed at baseline (mean age: 42.5 years; 88% women); 28 of the 50 (56%) patients continued therapy for 3 years. Among patients who continued therapy, MMDs decreased from 12.0 ± 5.4 to 5.6 ± 5.4 at 36 months, with parallel improvements in the MIDAS, HIT-6, and VAS (all p < 0.01). Responder rates were durable (≥50%: 55.6% at 36 months; ≥75%: 29.6%; 100%: 11.1%). Discontinuation frequently reflected treatment completion after goal attainment (24%); no adverse-event–related discontinuations occurred.ConclusionOver 3 years, anti-CGRP monoclonal antibodies provided sustained preventive effectiveness and favorable tolerability in routine practice, supporting individualized decision-making regarding continuation, planned discontinuation, and regimen selection.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontiersin.org/articles/10.3389/fneur.2026.1784653</guid>
        <link>https://www.frontiersin.org/articles/10.3389/fneur.2026.1784653</link>
        <title><![CDATA[Prevalence of delirium among patients with advanced cancer: a systematic review and meta-analysis]]></title>
        <pubdate>2026-05-13T00:00:00Z</pubdate>
        <category>Systematic Review</category>
        <author>Linshan Jiang</author><author>Zhongyin Zhang</author><author>Xiaojun Liu</author><author>Yanxing Jiang</author><author>Qianqian Mou</author>
        <description><![CDATA[BackgroundDelirium is a prevalent complication experienced by patients with advanced cancer and is associated with various adverse outcomes. Although delirium is widely reported among patients with advanced cancer, its estimated prevalence shows considerable heterogeneity across studies. This study aimed to determine the prevalence of delirium among patients with advanced cancer.MethodsA comprehensive literature search was conducted across ten major electronic databases from their inception to September 15, 2025. Data extraction was undertaken using a structured data collection form, and methodological quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal tool for prevalence studies. A random-effects model was used to estimate the pooled prevalence of delirium. Heterogeneity was evaluated using the I2 statistic, with subgroup analyses performed to explore its potential sources.ResultsA total of 17 studies comprising 9,007 patients with advanced cancer yielded a pooled delirium prevalence of 35.6% (95% CI: 27.2–44.1). 13 studies were appraised as having a low overall risk of bias, while 4 were considered to have a moderate risk of bias. The results of subgroup analysis indicated that the pooled prevalence of delirium among patients with advanced cancer exhibited significant variation depending on the assessment tool employed.ConclusionOur findings indicated that delirium is highly prevalent among patients with advanced cancer, highlighting the necessity for early screening, prevention, and treatment. However, these results should be interpreted with caution due to limitations such as the small sample size and considerable heterogeneity. Moreover, the inclusion of only three studies from developing countries limits generalizability to low-resource settings.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251167526.]]></description>
      </item>
      </channel>
    </rss>